JPWO2021240436A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021240436A5
JPWO2021240436A5 JP2022573173A JP2022573173A JPWO2021240436A5 JP WO2021240436 A5 JPWO2021240436 A5 JP WO2021240436A5 JP 2022573173 A JP2022573173 A JP 2022573173A JP 2022573173 A JP2022573173 A JP 2022573173A JP WO2021240436 A5 JPWO2021240436 A5 JP WO2021240436A5
Authority
JP
Japan
Prior art keywords
antibody
use according
subject
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022573173A
Other languages
English (en)
Japanese (ja)
Other versions
JP7841752B2 (ja
JP2023527200A (ja
JP2023527200A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/054652 external-priority patent/WO2021240436A1/en
Publication of JP2023527200A publication Critical patent/JP2023527200A/ja
Publication of JPWO2021240436A5 publication Critical patent/JPWO2021240436A5/ja
Publication of JP2023527200A5 publication Critical patent/JP2023527200A5/ja
Application granted granted Critical
Publication of JP7841752B2 publication Critical patent/JP7841752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022573173A 2020-05-29 2021-05-27 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法 Active JP7841752B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063032035P 2020-05-29 2020-05-29
US63/032,035 2020-05-29
US202063077378P 2020-09-11 2020-09-11
US63/077,378 2020-09-11
EP21315081.6 2021-05-11
EP21315081 2021-05-11
PCT/IB2021/054652 WO2021240436A1 (en) 2020-05-29 2021-05-27 Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis

Publications (4)

Publication Number Publication Date
JP2023527200A JP2023527200A (ja) 2023-06-27
JPWO2021240436A5 true JPWO2021240436A5 (https=) 2024-06-03
JP2023527200A5 JP2023527200A5 (https=) 2024-06-03
JP7841752B2 JP7841752B2 (ja) 2026-04-07

Family

ID=76269781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573173A Active JP7841752B2 (ja) 2020-05-29 2021-05-27 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法

Country Status (12)

Country Link
US (1) US20230192871A1 (https=)
EP (1) EP4157450A1 (https=)
JP (1) JP7841752B2 (https=)
KR (1) KR20230018443A (https=)
CN (1) CN115697486A (https=)
AU (1) AU2021279412A1 (https=)
BR (1) BR112022023949A2 (https=)
CA (1) CA3180041A1 (https=)
CO (1) CO2022017828A2 (https=)
IL (1) IL298087A (https=)
MX (1) MX2022015030A (https=)
WO (1) WO2021240436A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
AU2015317905A1 (en) * 2014-09-16 2017-03-16 Regeneron Pharmaceuticals, Inc. Compositions for improving the health related quality of life of rheumatoid arthritis patients

Similar Documents

Publication Publication Date Title
JP2024069453A5 (https=)
CN113423426B (zh) 使用抗FcRn抗体治疗格雷夫斯眼病的方法
JP6278536B2 (ja) 関節炎治療
RU2018100820A (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015514110A5 (https=)
RU2013155906A (ru) Антитела анти-angptl3 и их применение
JP2004510752A5 (https=)
JP2019521647A5 (https=)
TWI677504B (zh) Btla同效劑抗體及其用途
CN104995210A (zh) 类风湿关节炎的治疗
JP6949012B2 (ja) B型肝炎表面抗原に対する抗体及びその使用
JPWO2019209995A5 (https=)
CN114762678B (zh) 抗tigit抗体药物组合物及其用途
CA2290021A1 (en) Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
JP2021511024A5 (https=)
CN101878037A (zh) 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途
JP2025072440A5 (https=)
JP2025087764A5 (https=)
CN106573059A (zh) 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
US20140065154A1 (en) Tlr3 binding agents
JPWO2021240436A5 (https=)
JPWO2020247461A5 (https=)
WO2022184114A1 (zh) 抗il-17抗体治疗自身免疫性疾病和炎症的方法
RU2021138376A (ru) Композиции и способы лечения боли у субъектов с ревматоидным артритом
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法